Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
DeLLphi-307 trial: what clinicians have said so far
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
- NCT06502977 ↗
- Active, not recruiting
- Amgen
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on DeLLphi-307 (tarlatamab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DeLLphi-307 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Tarlatamab
- Arms
- Tarlatamab · Experimental
- Enrollment
- 32
- Primary outcomes
- Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Sponsor
- Amgen
- Start
- Aug 27, 2024
- Primary completion
- Mar 28, 2025
- Results posted
- Yes
- Registry record
- NCT06502977 · updated Oct 21, 2026